Last reviewed · How we verify
Deuremidevir Hydrobromide for Suspension — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Deuremidevir Hydrobromide for Suspension (Deuremidevir Hydrobromide for Suspension) — Vigonvita Life Sciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Deuremidevir Hydrobromide for Suspension TARGET | Deuremidevir Hydrobromide for Suspension | Vigonvita Life Sciences | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Deuremidevir Hydrobromide for Suspension CI watch — RSS
- Deuremidevir Hydrobromide for Suspension CI watch — Atom
- Deuremidevir Hydrobromide for Suspension CI watch — JSON
- Deuremidevir Hydrobromide for Suspension alone — RSS
Cite this brief
Drug Landscape (2026). Deuremidevir Hydrobromide for Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/deuremidevir-hydrobromide-for-suspension. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab